Rex E. Wiggins

TVAX Biomedical, Inc. manufactures and sells healthcare products. It is a biotechnology company, which focuses on the development of targeted cell-based immunotherapies for the treatment of cancer and is performing clinical trials with specific focus on brain cancers. The firm’s proprietary immunologic treatment, TVAX Immunotherapy, uses a patient's cells to create activated, genetically unique cancer-killing T cells that can destroy the patient's cancer cells, including cancer stem cells, which are widely believed to be responsible for cancer growth, spread and metastasis. The company was founded by Gray W. Wood, Frank P. Holladay, Catherine E. Lucasey and Lowell Lynn Tilzer on July 14, 2011 and is headquartered in Lenexa, KS.